Alimta ANDA Products Hit Double Digits With Several Launches
Fresenius Kabi Has ‘Broadest Portfolio Available’
Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.
You may also be interested in...
Hot on the heels of the first US generic Nexavar launch by Viatris, Dr Reddy’s has followed with a second sorafenib rival. The product represents the latest in a string of significant US launches for the Indian company.
Sandoz has launched its generic pemetrexed rival to Alimta in a ready-to-dilute 1,000mg presentation in 11 EU countries including Germany, Switzerland, the Netherlands and Spain.
Sawai is lining up eight launches as part of the Japanese company’s strategy to capture an increased share of its domestic generics market.